|OliX Pharmaceuticals to Participate in BIO-Europe Spring®|
|Date : 2022-03-24 View : 566|
OliX Pharmaceuticals to Participate in BIO-Europe Spring®
SUWON, South Korea -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that the Company’s management will participate in one-on-one partnering meetings at BIO-Europe Spring. The event is being held digitally from March 28-31, 2022.
Dr. Sun Woo Hong, Head of External Collaboration, and Dr. June Park, Principal Scientist, will meet industry experts to discuss platform-based early discovery collaborations as well as global licensing options for pipeline programs, including OLX101A for hypertrophic scars (Phase 2), OLX703A for hepatitis B virus, and OLX702A for nonalcoholic steatohepatitis.
This year, BIO-Europe Spring, Europe’s largest springtime biopharma industry gathering, will serve the global biotechnology industry, including more than 1000 companies from 45 countries. To schedule a virtual meeting, please visit the BIO-Europe Spring® platform at https://informaconnect.com/bioeurope-spring/partnering/.
|Prev||OliX Identifies Inhibition of Target Gene expression in Nonhuman Primate Models for NASH Candidate|
|Next||OliX Pharmaceuticals Presents Potential Utility of GalNAc-asiRNA Platform at OPT Congress|